Nurx Works with Gifthealth to Streamline Access to Lilly's Medication Zepbound®
NEW YORK, April 9, 2025 /PRNewswire/ -- Nurx, a leading telehealth platform specializing in women's health, is excited to announce an integration agreement with Gifthealth, Eli Lilly and Company's LillyDirect® pharmacy provider, for Zepbound® (tirzepatide) single-dose vials to simplify prescription access. The arrangement will streamline access to the vials for clinically-eligible Nurx patients with an on-label prescription, ensuring they have a more seamless way to receive chronic weight management treatment.
Obesity and overweight affect more than 2 out of 3 women over the age of 20 in the United States and is a risk that increases with age. What's more, 11.5% of women have severe obesity, a higher rate than in men. Overweight and obesity have profound health implications, increasing the risks of cardiovascular disease, type-2 diabetes, certain cancers, and complications during pregnancy. This is why addressing overweight and obesity is crucial for improving women's health overall. However, losing weight and keeping it off can be challenging: studies show that only 1 in 10 adults with overweight and obesity achieve weight loss of 5% or more each year.
Recognizing these challenges, Nurx is committed to providing women with effective, evidence-based weight management solutions. This integration with Gifthealth will streamline access to Zepbound®, an FDA-approved medication for obesity and chronic weight management, for clinically-eligible patients with an on-label prescription from a Nurx-affiliated provider. This integration arrangement also underscores Nurx's dedication to empowering women with the tools and support necessary to achieve their health goals.
As demand for obesity and chronic weight management medications like Zepbound® continues to rise, Nurx is committed to providing comprehensive telehealth care for women navigating weight management. By integrating Gifthealth's pharmacy fulfillment capabilities, Nurx patients will benefit from streamlined access to Zepbound® vials, and can take advantage of Gifthealth's transparent pricing and nationwide delivery — key factors in making obesity care more accessible.
"At Nurx, we believe that every woman deserves access to the healthcare solutions that best fit her needs — including safe and effective weight management medications," said Rajani Rao, Chief Business Officer at Nurx. "This integration agreement with Gifthealth allows us to streamline barriers to access, ensuring women can get the medication they need, and pair it with Nurx's comprehensive approach to weight management, which provides ongoing access to physicians and support in making lifestyle changes."
Gifthealth has been at the forefront of prescription innovation. This new integration agreement with Nurx will help streamline the prescription fulfillment process for weight management treatments, reinforcing both companies' missions to provide affordable, high-quality care. "We are excited to work with providers such as Nurx to streamline access to authentic Zepbound® vials for women nationwide," said Robert Hoppe, EVP of Life Sciences at Gifthealth. "Our goal is to remove cost and logistical barriers to essential medications, and through these integrations, we can help more patients get the care they need."
About Nurx by Thirty MadisonNurx is the leading women's healthcare company making high-quality, judgment-free care accessible and affordable for millions. By removing barriers like cost, stigma, and provider shortages, we provide convenient, personalized treatment across 20+ conditions, including reproductive and sexual health, dermatology, mental health, migraine, hair loss, and weight management. With over 2 million patients served and more than 600,000 actively receiving care, Nurx connects patients directly with trusted healthcare providers and delivers treatment right to their doorstep — ensuring ongoing, specialty-level support that evolves with their needs.
About Thirty Madison Thirty Madison offers end-to-end, high-quality virtual specialized care for patients experiencing a range of conditions. Through its brands — Keeps for men's hair loss, Cove for migraine, and Nurx for women's health — Thirty Madison supports the unique needs of its patients with ongoing access to personalized care and specialty-level telemedicine. Thirty Madison's unique care model delivers care that is accessible, affordable, and focused on improving outcomes. Learn more at ThirtyMadison.com.
About Gifthealth Gifthealth is a digital pharmacy solution founded in 2020, focused on simplifying the prescription process for patients, providers, and manufacturers. By leveraging technology, Gifthealth ensures cost-effective medication access, with a mission to improve adherence and health outcomes. Learn more at gifthealth.com.
Media Contact:Stephanie HallPitch Public Relations480.216.5433 | Stephanie@Pitchpublicrelations.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/nurx-works-with-gifthealth-to-streamline-access-to-lillys-medication-zepbound-302423940.html
SOURCE Nurx
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
The British Medical Journal Publishes Study Results on Sacituzumab Tirumotecan for Previously Treated EGFR-Mutant Advanced NSCLC
CHENGDU, China, June 6, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", today announced that results from its registrational study (OptiTROP-Lung03) evaluating sacituzumab tirumotecan (sac-TMT) versus docetaxel in patients with previously treated advanced EGFR-mutant non-small cell lung cancer (NSCLC) have been published in The British Medical Journal (impact factor: 93.6). These data were also presented as an oral presentation in the Lung Cancer—Non–Small Cell Metastatic session (Abstract #8507) at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Based on the encouraging data from this study, sac-TMT was approved for marketing by the National Medical Products Administration (NMPA) for the treatment of adult patients with epidermal growth factor receptor (EGFR) mutant-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-tyrosine kinase inhibitor (TKI) therapy and platinum-based chemotherapy in March 2025. This marks the first global approval of a TROP2 ADC for a lung cancer indication. The published results are based on OptiTROP-Lung03, an open-label, randomized, multicenter registrational study evaluating the efficacy and safety profile of sac-TMT monotherapy versus docetaxel for the treatment of patients with locally advanced or metastatic EGFR-mutant NSCLC who have failed after treatment with an EGFR-TKI and platinum-based chemotherapy. A total of 137 patients with advanced EGFR-mutant NSCLC who had progressed after EGFR-TKI and platinum-based chemotherapy were randomized (2:1) to receive sac-TMT (5 mg/kg once every 2 weeks) or docetaxel (75 mg/m2 once every 3 weeks) until disease progression, intolerable toxicity or other reason for discontinuation, with a median follow-up time of 12.2 months (Data cutoff date: December 31, 2024). Sac-TMT achieved statistically significant and clinically meaningful outcomes compared to docetaxel: Confirmed objective response rate (ORR) (As assessed by blinded independent review committee (BIRC): 45% (95% CI, 35-56) vs 16% (95% CI, 7-30). Median progression-free survival (PFS) (As assessed by BIRC: 6.9 months [sac-TMT; 95% CI, 5.4-8.2] vs 2.8 months [docetaxel; 95% CI, 1.6-4.1], hazard ratio (HR)= 0.30 [range, 0.20 -0.46], one-sided p<0.0001; as assessed by investigator (INV): 7.9 months [sac-TMT; 95% CI, 6.2-9.5] vs 2.8 months [docetaxel; 95% CI, 1.5-3.8], HR=0.23 [95% CI, 0.15-0.36], one-sided p<0.0001). With 36.4% of patients in docetaxel group crossing over to receive sac-TMT, median overall survival (OS) was not reached (NR) for both groups (HR=0.49; 95% CI, 0.27-0.88; one-sided p=0.007). The median OS analysed by pre-specified rank-preserving structural failure time (RPSFT) model adjusted for crossover was 9.3 months for docetaxel and NR for sac-TMT (HR=0.36; 95% CI, 0.20-0.66). Efficacy benefit favored patients with sac-TMT over docetaxel across all pre-specified subgroups, including prior EGFR-TKI therapy, brain metastases, EGFR mutation type, etc. Grade ≥ 3 treatment-related adverse events (TRAEs) occurred in 56.0% of patients in sac-TMT group vs 71.7% in docetaxel group. The results demonstrated that sac-TMT monotherapy achieved statistically significant and clinically meaningful improvements in objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) compared to docetaxel, with a manageable safety profile. Sac-TMT is being extensively studied in the NSCLC field. Covering treatment settings from later-line therapy to early-stage postoperative adjuvant therapy, including both monotherapy and combination regimens. Currently, five company-led registrational clinical studies for sac-TMT in NSCLC are underway in China. Meanwhile, Merck Sharp & Dohme（the tradename of Merck & Co., Inc., Rahway, NJ, USA）is also conducting five global Phase III clinical trials of sac-TMT for NSCLC in regions where it has exclusive rights. Professor Li Zhang, National Lead Principal Investigator, Medical Oncologist and Deputy Director of the Lung Cancer Research Centre at Sun Yat-Sen University, stated: "EGFR mutation is the most common driver alteration in NSCLC. The prevalence of EGFR mutations reaches 28.2% among NSCLC patients in China. Although third-generation EGFR-TKIs have become the standard of care for advanced EGFR-mutant NSCLC and may significantly improve PFS, acquired resistance remains inevitable. Combining EGFR-TKIs with chemotherapy can offer additional survival benefits to some patients, but this approach is limited by safety concerns and may compromise future treatment options, posing significant clinical challenges. The publication of the OptiTROP-Lung03 study in the British Medical Journal marks a major milestone—not only highlighting international recognition of this study outcomes in lung cancer, but also demonstrating the global competitiveness of sac-TMT as a novel TROP2 ADC." Dr. Michael Ge, CEO of Kelun-Biotech, commented: "We are thrilled to see the OptiTROP-Lung03 study published in a top-tier journal. Currently, EGFR-TKIs and chemotherapy remain the standard of care for patients with EGFR-mutant advanced NSCLC, but the challenge of increasing efficacy with manageable tolerability. The results from OptiTROP-Lung03 highlight significant survival benefits with manageable safety profile and suggest that sac-TMT could emerge as a new standard of care for this population. We remain committed to working with our partners to establish sac-TMT as a new standard of care for this patient population and improve outcomes for lung cancer patients worldwide." Registrational Study Led by Kelun-Biotech OptiTROP-Lung03: Sac-TMT monotherapy versus docetaxel for locally advanced or metastatic EGFR-mutant NSCLC after treatment failure with EGFR-TKI and platinum-containing chemotherapy； OptiTROP-Lung04: Sac-TMT monotherapy versus pemetrexed in combination with platinum for locally advanced or metastatic non-squamous NSCLC with EGFR mutations that have failed EGFR-TKI therapy； OptiTROP-Lung05: Sac-TMT combined with pembrolizumab versus chemotherapy combined with pembrolizumab for first-line treatment of PD-L1-positive locally advanced or metastatic NSCLC; OptiTROP-Lung06: Sac-TMT combined with pembrolizumab versus chemotherapy combined with pembrolizumab for the first-line treatment of PD-L1-negative locally advanced or metastatic non-squamous NSCLC; OptiTROP-Lung07: First-line treatment of locally advanced or metastatic NSCLC with EGFR mutations by sac-TMT in combination with ositinib. Registrational Study Led by MSD NSCLC not achieving a pCR after neoadjuvant therapy followed by surgery. NSCLC expressing PD-L1 >50% pre-treated NSCLC with EGFR mutations or other genomic alterations EGFR-mutated, advanced non-squ NSCLC progressed on prior EGFR-TK metastatic sg NSCLC About sac-TMT Sac-TMT, a core product of the Company, is a novel human TROP2 ADC in which the Company has proprietary intellectual property rights, targeting advanced solid tumors such as NSCLC, BC, gastric cancer (GC), gynecological tumors, among others. Sac-TMT is developed with a novel linker to conjugate the payload, a belotecan-derivative topoisomerase I inhibitor with a drug-to-antibody-ratio (DAR) of 7.4. Sac-TMT specifically recognizes TROP2 on the surface of tumor cells by recombinant anti-TROP2 humanized monoclonal antibodies, which is then endocytosed by tumor cells and releases KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable, it can enable a bystander effect, or in other words kill adjacent tumor cells. In May 2022, the Company licensed the exclusive rights to MSD (the tradename of Merck & Co., Inc., Rahway, NJ, USA) to develop, use, manufacture and commercialize sac-TMT in all territories outside of Greater China (includes Mainland China, Hong Kong, Macao, and Taiwan). To date, two indications for sac-TMT have been approved and marketed in China for the treatment of adult patients with unresectable locally advanced or metastatic TNBC who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting) based on the OptiTROP-Breast01 study and EGFR mutation-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-TKI therapy and platinum-based chemotherapy based on the OptiTROP-Lung03 study. Sac-TMT became the first domestic ADC with global intellectual property rights to be fully approved for marketing. It is also the world's first TROP2 ADC to be approved for marketing in a lung cancer indication. In addition, two new indication applications for sac-TMT for the treatment of adult patients with EGFR-mutant locally advanced or metastatic NSCLC who progressed after treatment with EGFR-TKI therapy and with unresectable locally advanced, metastatic hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) BC who have received prior endocrine therapy and other systemic treatments in the advanced or metastatic setting were accepted by the National Medical Products Administration (NMPA), and were reviewed via the priority review and approval process. As of today, the Company has initiated 8 registrational clinical studies in China. MSD has initiated 14 ongoing Phase 3 global clinical studies of sac-TMT as a monotherapy or with pembrolizumab or other agents for several types of cancer. These studies are sponsored and led by MSD. About Kelun-Biotech Kelun-Biotech（ a holding subsidiary of Kelun Pharmaceutical ( which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. The company focuses on major disease areas such as solid tumors, autoimmune, inflammatory, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. The Company is committed to becoming a leading global enterprise in the field of innovative drugs. At present, the Company has more than 30 ongoing key innovative drug projects, of which 3 projects have been approved for marketing, 1 project is in the NDA stage, and more than 10 projects are in the clinical stage. The company has established one of the world's leading proprietary ADC platforms, OptiDC™, and has 1 ADC project approved for marketing, 1 ADC project in NDA stage, and multiple ADC and novel coupled drug products in clinical or preclinical research stage. For more information, please visit Media: klbio_pr@ View original content to download multimedia: SOURCE Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Yahoo
an hour ago
- Yahoo
ProZenith Launches Natural Supplement Formulated for Weight Management Support
U.S.-Made Product Supports General Wellness Goals with a 60-Day Refund Policy Aurora, June 06, 2025 (GLOBE NEWSWIRE) -- ProZenith recently announced the launch of its new wellness supplement developed to assist individuals in maintaining energy, focus, and mindful appetite awareness as part of a balanced and active lifestyle. Manufactured in the United States in a facility that is FDA-registered and GMP-certified, the product is now available through official online channels. ProZenith is intended for individuals pursuing support for general weight management and overall well-being. Its formulation includes select ingredients chosen to align with healthy routines and support individuals seeking help managing non-hunger-related snacking behaviors. Each purchase of ProZenith is covered by a 60-day refund policy, reflecting the company's customer-first return assurance framework. All ProZenith supplements are manufactured without genetically modified ingredients and adhere to U.S. quality standards. Production takes place in an FDA-registered facility that complies with current Good Manufacturing Practices (cGMP). ProZenith is currently available through the company's official online platform at with multiple purchase options provided for convenience. About ProZenith ProZenith develops nutritional supplements designed to support individuals on their wellness journeys. The company emphasizes high-quality manufacturing, transparency, and customer satisfaction as it continues to expand its product offerings for health-conscious consumers. For customer support inquiries, contact:support@ Disclaimer:This product has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Media Contact: Company: ProZenith Address: 19655 E 35th Dr #100, Aurora, CO 80011 Email: support@ Order Phone Support: (925) 217-7353 CONTACT: Company: ProZenith Address: 19655 E 35th Dr #100, Aurora, CO 80011 Email: support@ Order Phone Support: (925) 217-7353Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Newsweek
an hour ago
- Newsweek
Egg Recall Map Shows Warnings Issued to Customers in 9 States
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. August Egg Company has issued a recall on Friday for 1,700,000 brown cage-free and certified organic brown eggs due to potential fears of salmonella. Newsweek reached out to the company after hours via phone Friday night for comment. Why It Matters Numerous recalls have been initiated this year due to the potential for the following: damaged products, foodborne illness, contamination and undeclared food allergens. Millions of Americans experience food sensitivities or food allergies every year. According to the Food and Drug Administration (FDA), the nine "major" food allergens in the U.S. are eggs, milk, fish, wheat, soybeans, Crustacean shellfish, sesame, tree nuts and peanuts. The FDA warns that salmonella is an organism that could cause serious and sometimes fatal infections in frail or older people, young children and those with weakened immune systems. What To Know The FDA says in its alert that some of the eggs were distributed to grocery stores including Save Mart, FoodMaxx, Lucky, Smart & Final, Safeway, Raleys, Food 4 Less and Ralphs. Those eggs were distributed from February 3, 2025, to May 15, 2025, with sell by dates of March 4, 2025, and June 4, 2025, in both California and Nevada. The FDA says additional eggs were distributed from February 3, 2025, to May 6, 2025, with sell by dates of March 4, 2025, and June 19, 2025, in Walmart stores in Illinois, Indiana, Nebraska, New Mexico, California, Washington, Nevada, Arizona and Wyoming. The plant code numbers for the recalled eggs can be found printed on the package and are P-6562 or CA5330 with Julian Dates from 32 to 126, the FDA says. The Julian Dates are codes of three to seven digits and represent the date that the food was packaged or manufactured. "This recall is associated with an ongoing outbreak investigation of Salmonella Enteritidis illnesses" the alert says, adding the investigation is related to products distributed in the nine states. The FDA alert also has a chart of the Julian Dates with corresponding item names. What People Are Saying The FDA alert, in part: "August Egg Company is not selling fresh shell eggs at this time. Our firm has voluntarily been diverting eggs to an egg-breaking plant for over 30 days, which pasteurizes the eggs and kills any potential foodborne pathogens." August Egg Company in the FDA alert: "August Egg Company of Hilmar, CA is voluntarily recalling 1,700,000 dozen shell eggs processed at our California plant and sold to various grocery customers. This recall has been initiated due to possible Salmonella enteritidis contamination, which poses a health risk. With that in mind, we believe it is appropriate out of an abundance of caution to conduct this voluntary recall, as consumers may still have these eggs in their homes. "It is important to know that when our processing plant identified this concern, we immediately began diverting all eggs from the plant to an egg-breaking facility, which pasteurizes the eggs and kills any pathogens. "August Egg Company's internal food safety team also is conducting its own stringent review to identify what measures can be established to prevent this situation from recurring. We are committed to addressing this matter fully and to implementing all necessary corrective actions to ensure this does not happen again." What Happens Next Customers with additional questions can call August Egg Company at 1-800-710-2554 from 9 a.m. and 5 p.m. PT and can also return the eggs to the original place of purchase for a refund.
